Standards of laboratory practice: Cardiac drug monitoring

Clinical Chemistry

Volumn 44, Issue 5, 1998, Pages 1096-1109

  Valdes Jr , Roland ^a   Jortani, Saeed A ^a   Gheorghiade, Mihai ^b  

^a University of Louisville School of Medicine   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACECAINIDE; AMIODARONE; ANTIANGINA PECTORIS AGENT; ANTIARRHYTHMIC AGENT; CARDIAC AGENT; CARDIAC GLYCOSIDE; DIGITOXIN; DIGOXIN; DISOPYRAMIDE PHOSPHATE; FLECAINIDE ACETATE; LIDOCAINE; MEXILETINE; PROCAINAMIDE; PROPAFENONE; QUINIDINE SULFATE;

ANGINA PECTORIS; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DRUG CROSS REACTIVITY; DRUG HALF LIFE; DRUG MONITORING; DRUG STABILITY; DYSPNEA; GOOD LABORATORY PRACTICE; HEADACHE; HEART ARRHYTHMIA; HEART PALPITATION; HUMAN; HYPOTENSION; NAUSEA; PHOTOSENSITIVITY DISORDER; RASH; SLEEP DISORDER; TASTE DISORDER; THYROID DISEASE; TREMOR; VISUAL DISORDER; VOMITING;

ANGINA;

EID: 15644372401     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.5.1096     Document Type: Conference Paper

References (118)

1. Robertson RM, Robertson D. Drugs used for the treatment of myocardial ischemia. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, eds. Goodman and Gilman's pharmacological basis of therapeutics, 9th ed. Chapter 32, New York: McGraw Hill, 1996:759-79.
2. Roden DM. Antiarrhythmic drugs. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, eds. Goodman and Gilman's pharmacological basis of therapeutics, 9th ed. Chapter 35, New York: McGraw Hill, 1996:839-73.
3. Physicians' desk reference. Lanoxin tablets. Montvale, NJ: Medical Economics Co., 1997:1119-24.
4. Vaughan Williams EM. Classification of antiarrhythmic drugs. In: Sondoe E, Flensted-Jensen E, Olsen EH, eds. Symposium on cardiac arrhythmias. Amsterdam: Elsevier, 1970:449-501.
5. Kay GN, Bubien RS. Pharmacologic treatment of arrhythmias. In: Kay GN, Bubien RS, eds. Clinical management of cardiac arrhythmias. Gaithersburg, MD: Aspen Publishers, 1991:73-98.
6. Harrison DC. Antiarrhythmic drug classification: new science and practical applications. Am J Cardiol 1985;56:185-7.
7. Bryson HM, Palmer KJ, Langtry HD, Fitton A. Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias (Review). Drugs 1993;45:85-130.
8. Morike KE, Roden DM. Quinidine-enhanced β-blockade during treatment with propafenone in extensive metabolizer human subjects. Clin Pharmacol Ther 1994;55:28-34.
9. Harpat SR, Kates RE. High-performance liquid chromatographic analysis of propafenone in human plasma samples. J Chromatogr 1982;230:448-53.
10. Steurer G, Weber H, Schmidinger H, Plass H, Frey B, Purerfellner H, Probst P. Plasma propafenone concentration in the evaluation of anti-arrhythmic efficacy. Eur Heart J 1991;12:526-32.
11. Kroemer HK, Fromm MF, Buhl K, Terefe H, Blaschke G, Eichelbaum M. An enantiomer-enantiomer interaction of (S)-and (R)-propafenone modifies the effect of racemic drug therapy. Circulation 1994;89:2396-400.
12. Physicians' desk reference. Cordarone intravenous. Montvale, NJ: Medical Economics Co., 1997:2821-4.
13. Pollak PT, Sharma AD, Carruthers SG. Correlation of amiodarone dosage, QT interval and coreal microdeposits with serum amiodarone and desethylamiodarone concentrations. Am J Cardiol 1989;64:1138-43.
14. Mamolo MG, Vio L, Furlan G. Simultaneous determination of amiodarone and desethylamiodarone in human plasma by high performance liquid chromatography. Farmaco 1992;47:1067-80.
15. Manfredi C, Clerico A, Iervasi G, Turchi S, Cazzuola F, Berti S, et al. Measurement of serum amiodarone and desethylamiodarone by HPLC: its usefulness in the follow-up of arrhythmic patients treated with amiodarone. Int J Clin Pharmacol Res 1995;15:87-93.
16. Maling TJ, Siebers RW, Burgess CD, Taylor C, Purdie G. Individual variability of amiodarone distribution in plasma and erythrocytes: implications for therapeutic monitoring. Ther Drug Monit 1989; 11:121-6.
17. Fenster PE, Comess KA. Pharmacology and clinical use of mexiletine. Pharmacotherapy 1986;6:1-9.
18. Woosley RL, Wang T, Stone W, Siddoway L, Thompson K, Duff HJ, et al. Pharmacology, electrophysiology, and pharmacokinetics of mexiletine. Am Heart J 1984;107:1058-65.
19. Kendall JD, Chrymko MM, Cooper BE. Theophylline-mexiletine interaction: a case report. Pharmacotherapy 1992;12:416-8.
20. Meoli P, Sanna GP, Rovelli F. Clinical study evaluated by Holter monitoring and by mexiletine serum levels in ventricular arrhythmias. G Ital Cardiol 1982;12:115-21.
21. Paczkowska W, Filipek M, Mielniczuk Z, Andrzejczak J, Poplawska W, Sitkiewics D. Simultaneous determination of mexiletine and four hydroxylated metabolites in human serum by high-performance liquid chromatography and its application to pharmacokinetic studies. J Chromatogr 1992;573:235-46.
22. Paczkowski D, Podlensy J, Filipek M. A rapid HPLC method for plasma and serum mexiletine determination and its use in therapeutic drug monitoring. Pol J Pharmacol Pharm 1989;41: 459-67.
23. Minnigh MB, Alvin JD, Zemaitis MA. Determination of plasma mexiletine levels with gas chromatography-mass spectrometry and selected-ion monitoring. J Chromatogr B: Biomed Appl 1994;662:118-22.
24. Hoffman BF, Bigger T Jr. Digitalis and allied cardiac glycosides. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's pharmacological basis of therapeutics, 8th ed. New York: Macmillan, 1990:814-39.
25. Rose AM, Valdes R Jr. Understanding the sodium pump and its relevance to disease (Review). Clin Chem 1994;40:1674-85.
26. Reuning RH, Geraets DR. Digoxin. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics, principles of therapeutic drug monitoring, 2nd ed. Spokane, WA: Applied Therapeutics, 1986:570-97.
27. Doherty JE, Dalrymple GV, Murphy ML, Kane JJ, Bissett JK, de Soyza N. Pharmacokinetics of digoxin. Fed Proc 1977;36:2242-6.
28. Gault MH, Longerich LL, Loo JCK, Fine A, Ko PT, Vasdez SC, Dawe MA. Digoxin biotransformation. Clin Pharmacol Ther 1984; 35:74-81.
29. Gault MH, Charles JD, Sugden DI, Kepkay DC. Hydrolysis of digoxin by acid. J Pharm Pharmacol 1980;29:27-32.
30. Lindenbaum J, Rund DG, Butler VP, Tse-eng D, Saha JR. Inactivation of digoxin by gut flora: reversai by antibiotic therapy. N Engl J Med 1981;305:789-94.
31. Bednarczyk B, Soldin SJ, Gasinka I, D'Costa M, Perrot L. Improved receptor assay for measuring digoxin activity. Clin Chem 1988;34:393-7.
32. Pederson KE, Christiansen DB, Kligaard NA. Effects of quinidine on digoxin bioavailability. Eur J Clin Pharmacol 1983;24:41-7.
33. Hedman A. Inhibition of basic drugs of digoxin secretion into human bile. Eur J Clin Pharmacol 1992;42:457-9.
34. Hori R, Okamura N, Aiba T, Tanigawara Y. Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. J Pharmacol Exp Ther 1993;266:1620-5.
35. Mordel A, Haklin H, Zulty L, Almog S, Ezra D. Quinidine enhances digitalis toxicity at therapeutic serum digoxin levels. Clin Pharmacol Ther 1993;53:457-62.
36. Leahey EB. Digoxin-quinidine interaction: current status. Ann Intern Med 1980;93:775-6.
37. Jortani SA, Valdes R Jr. Digoxin and its related endogenous congeners. Crit Rev Clin Lab Sci 1997;34:225-74.
38. Physicians' desk reference. Procanbid tablets. Montvale, NJ: Medical Economics Co., 1997:1983-5.
39. Karlsson E, Molin L, Norlander B, Sjoqvist F. Acetylation of procainamide in man studied with a new gas chromatographic method. Br J Clin Pharmacol 1974;1:467-75.
40. Benet LZ, Kroetz DL, Sheiner LB. Pharmacokinetics: the dynamic of drug absorption, distribution, and elimination. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, eds. Goodman and Gilman's pharmacological basis of therapeutics, 9th ed. Chapter 32, New York: McGraw Hill, 1996:3-27.
41. Funck-Brentano C, Light RT, Lineberry MD, Wright GS, Roden DM, Woosley RL. Pharmacokinetic and pharmacokinetic interaction of N-acetyl procainamide and procainamide in humans. J Cardiol Pharmacol 1989;14:364-73.
42. Tisdale JE, Rudis MI, Padsi ID, Svensson CK, Webb CR, Borzak S. et al. Inhibition of N-acetylation of procainamide and renal clearance of N-acetylprocainamide by para-aminobenzoic acid in humans. J Clin Pharmacol 1995;35:902-10.
43. Speeg KV, Christian CD, McKinney TD. Inhibition of procainamide renal secretion by cimetidine: degree of inhibition is related to basal secretory rate (Abstract). Clin Pharmacol Ther 1987;41: 157.
44. Somogyi A, Bochner F. Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance. Br J Clin Pharmacol 1984;18:175-81.
45. Soonhang C, Karlssson E. Comparative antiarrhythmic efficacy of intravenous N-acetylprocainamide and procainamide. Eur J Clin Pharmacol 1979;15:311-7.
46. Moyer TP, Pippenger CE. Therapeutic drug monitoring. In: Burtis CA, Ashwood ER, eds. Tietz textbook of clinical chemistry, 2nd ed. Philadelphia: WB Saunders, 1994:1094-154.
47. Lima JJ, Jusko WJ. Determination of procainamide acetylator status. Clin Pharmacol Ther 1978;23:25-9.
48. Raphanaud D, Borensztejn M, Dupeyron JP, Guyon F. High performance liquid chromatography of procainamide and N-acetylprocainamide in human blood plasma. Ther Drug Monit 1986;8:365-7.
49. Tamai G, Yoshida H, Imai HJ. High-performance liquid chromatographic drug analysis by direct injection of whole blood samples. II. Determination of hydrophilic drugs. J Chromatogr 1987;423: 155-61.
50. Hondeghem L, Katzung BG. Test of a model for antiarrhythmic drug action, effects of quinidine and lidocaine on myocardial conduction. Circulation 1980;61:1217-24.
51. Physicians' desk reference. Quinidine tablets. Montvale, NJ: Medical Economics Co., 1997:2240-3.
52. Karagueuzian HS, Mandel WJ. Antiarrhythmic drugs: mode of action, pharmacokinetic properties, and therapeutic use. In: Mandel WJ, ed. Cardiac arrhythmias, their mechanisms, diagnosis, and management, 3rd ed. Philadelphia: JB Lippincott, 1995: 111-72.
53. Baselt RC, Cravey RH. Quinidine. In: Baselt RC, Cravey RH, eds. Disposition of toxic drugs and chemicals in man, 4th ed. Foster City, CA: Chemical Toxicology Institute, 1995:673-7.
54. Lehmann CR, Boran KJ, Pierson WP, Melikian AP, Wright GJ. Quinidine assays: enzyme immunoassay versus high performance liquid chromatography. Ther Drug Monit 1986;8:336-9.
55. Wooding-Scott RA, Darling IM, Slaughter RL. Comparison of assay procedures used to measure total and unbound concentrations of quinidine. DICP 1989;23:999-1004.
56. Schreiber V, Kolbel F, Hostlovaska M, Nedvidkova J. Endogenous quinidine-like immunoreactivity in the serum of rats with cardiac overload, stress or hyperthyroidism. Cor Vasa 1993;35:144-6.
57. Physicians' desk reference. Lidocaine injection. Montvale, NJ: Medical Economics Co., 1997:562-4.
58. Boyes RN, Scott DB, Jebson PJ, Godman MJ, Julian DG. Pharmacokinetics of lidocaine in man. Clin Pharmacol Ther 1970;12: 105-16.
59. Keenaghan JB, Boyes RN. The tissue distribution, metabolism and excretion of lidocaine in rats, guinea pigs, dogs and man. J Pharmacol Exp Ther 1972;180:454-63.
60. Blumer J, Strong JM, Atkinson AJ. The convulsant potency of lidocaine and its N-dealkylated metabolites. J Pharmacol Exp Ther 1973;186:31-6.
61. O'Neal C, Poklis A. Sensitive HPLC for simultaneous quantification of lidocaine and its metabolites monoethylglycinexylidide and glycinexylidide in serum (Tech Brief). Clin Chem 1996;42: 330-1.
62. Lorec AM, Bruguerolle B, Attolini L, Roucoules X. Rapid simultaneous determination of lidocaine, bupivacaine, and their two metabolites using capillary gas-liquid chromatography with nitrogen phosphorus detector. Ther Drug Monit 1994;16:592-5.
63. Physicians' desk reference. Disopyramide. Montvale, NJ: Medical Economics Co., 1997:2596.
64. Davis RF, Siddoway LA, Shaw L, Barbey JT, Roden DM, Woosley RL. Immediate versus controlled-release disopyramide: importance of saturable binding. Clin Pharmacol Ther 1993;54:16-22.
65. Meffin PJ, Robert EW, Winkle RA, Harapat S, Peters FA, Harrison DC. Role of concentration-dependent plasma protein binding in disopyramide disposition. J Pharmacokinet Biopharm 1979;7: 29-46.
66. 1-acid glycoprotein in patients with renal insufficiency. Ther Drug Monit 1995;17:449-53.
67. Baselt RC, Cravey RH. Disopyramide. In: Baselt RC, Cravey RH, eds. Disposition of toxic drugs and chemicals in man, 4th ed. Foster City, CA: Chemical Toxicology Institute, 1995:270.
68. Inagaki Y, Amano I, Otsu T. Accumulation of a disopyramide metabolite in renal failure. ASAIO J 1993;39:M609-13.
69. Bredesen JE, Pike E, Lunde PKM. Plasma binding of disopyramide and mono-N-dealkyldisopyramide. Br J Clin Pharmacol 1982;14:673-6.
70. Karim A. The pharmacokinetics of Norpace. Angiology 1975;26: 85-96.
71. Echizen H, Kawasaki H, Chiba K, Tani M, Ishizaki T. A potent inhibitory effect of erythromyocin and other macrolide antibiotics on the mono-N-dealkylation metabolism of disopyramide with human liver microsomes. J Pharmacol Exp Ther 1993;264: 1425-31.
72. Staum JM. Enzyme induction: rifampin-disopyramide interaction. DICP 1990;24:701-3.
73. Del Cont Bernard A, Royer Morrot MJ, Zhiri A, Rambourg M, Royer RJ. Automated determination of disopyramide and N-monodeal-kyldisopyramide in plasma by reversed-phase liquid chromatography with a column switching system. J Chromatogr 1992;574: 365-8.
74. Angelo HR, Bonde J, Kampmann JP, Kastrup J. A HPLC method for the simultaneous determination of disopyramide, lidocaine and their monodealkylated metabolites. Scand J Clin Lab Invest 1986;46:623-7.
75. Fenrich AL Jr, Perry JC, Friedman RA. Flecainide and amiodarone: combined therapy for refractory tachyarrhythmias in infancy. J Am Coll Cardiol 1995;25:1195-8.
76. Physicians' desk reference. Flecainide, Montvale, NJ: Medical Economics Co., 1997:1555.
77. Zordan R, Padrini R, Bernini V, Piovain D, Ferrari M. Influence of age and gender on the in vitro serum protein binding of flecainide. Pharmacol Res 1993;28:259-64.
78. Gross AS, Mikus G, Fischer C, Hertrampf R, Gundert-Remy U, Eichelbaum M. Stereoselective disposition of flecainide in relation to sparteine/debrisoquine metabolizer phenotype. Br J Clin Pharmacol 1989;28:555-6.
79. Baselt RC, Cravey RH, Flecainide. In: Baselt RC, Cravey RH, eds. Disposition of toxic drugs and chemicals in man, 4th ed. Foster City, CA: Chemical Toxicology Institute, 1995:322.
80. Hoppe U, Krudewagen B, Stein H, Hertrampf R. Comparison of fluorescence polarization immunoassay (FPIA) and high performance liquid chromatography (HPLC) methods for measurement of flecainide in human plasma. Int J Clin Pharmacol 1993;31: 142-7.
81. Lensmeyer GL, Weibe DA, Doran TC. Application of the Empore solid-phase extraction membrane to the isolation of drugs from blood. II. Mexiletine and flecainide. Ther Drug Monit 1992;14: 408-15.
82. McEroy GK, Litvak K, Welsh OH Jr. Cardiac glycosides. In: McEroy GK, Litvak K, Welsh OH Jr, eds. American hospital formulary services, 97 ed. Bethesda, MD: American Society of Health System Pharmacists, 1997:1176-84.
83. Bauer LA, Brown T, Gibaldi M, Hudson L, Nelson S, Raisys V, Shea JP. Influence of long-term infusions on lidocaine kinetics. Clin Pharmacol Ther 1982;31:433-7.
84. Lennard MS, Tucker GT, Woods HF. Time-dependent kinetics of lingocaine in the isolated perfused rat liver. J Pharmacokinet Biopharm 1983;11:165-82.
85. Feely J, Wade D, McAllister CB. Effects of hypertension on liver blood flow and lidocaine disposition. N Engl J Med 1982;307: 866-9.
86. Pieper JA, Rodman JH. Lidocaine. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics, principles of therapeutic drug monitoring, 2nd ed. Spokane WA: Applied Therapeutics, 1986:639-81.
87. Rangno RF, Warnica W, Ogilvie RL, Kreeft J, Bridger E. Correlation of disopyramide pharmacokinetics with efficacy in ventricular tachyarrhythmias. J Intern Med 1976;4:54-8.
88. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmias suppression after myocardial infarction. N Engl J Med 1989;321:386-8.
89. Bernard DW, Bowman RL, Grimm FA, Wolf BA, Simson MB, Shaw LM. Nighttime dosing assures postdistribution sampling for therapeutic monitoring of digoxin. Clin Chem 1996;42:45-9.
90. Miller JJ, Straub RW, Valdes R Jr. Digoxin immunoassay with cross-reactivities of digoxin metabolites proportional to their biological activity. Clin Chem 1994;40:1898-903.
91. Lowenstein JM. A method for measuring plasma level of digitalis glycosides. Circulation 1965;31:228-33.
92. Valdes R Jr. Endogenous digoxin-like immunoreactive factors: impact on digoxin measurements and potential physiological implications. Clin Chem 1985;31:1526-32.
93. Fushimi R, Koh T, Iyama S, Yasuhara M, Tachi J, Kohda K. Digoxin-like immunoreactivity in Chinese medicine. Ther Drug Monit 1990;12:242-5.
94. Osterloh J, Herold S, Pond S. Oleander interference in the digoxin radioimmunoassay in a fatal ingestion. JAMA 1982;247:1596-7.
95. Cheung K, Hinds JA, Duffy P. Detection of poisoning by plant-origin cardiac glycoside with the Abbott TDx analyzer. Clin Chem 1989;35:295-7.
96. +-ATPase by oleandrin and oleandrigenin, and their detection by digoxin immunoassays. Clin Chem 1996;42:1654-8.
97. Clark RF, Selden BS, Curry SC. Digoxin-specific Fab fragments in the treatment of oleander toxicity in a canine model. Ann Emerg Med 1991;20:1073-7.
98. Shumaik GM, Wu AW, Ping AC. Oleander poisoning: treatment with digoxin-specific Fab antibody fragments. Ann Emerg Med 1988;17:732-5.
99. Safadi R, Levy I, Amitai Y, Caraco Y. Beneficial effect of digoxin-specific Fab antibody fragments in oleander intoxication. Arch Intern Med 1995;155:2121-5.
100. Jortani SA, Miller JM, Helm RA, Johnson NA, Valdes R Jr. Suppression of immunoassay results by cross-reactivity. J Clin Ligand Assay 1997;20:177-9.
101. Rainey PM. Effects of digoxin immune Fab (ovine) on digoxin immunoassays. Am J Clin Pathol 1989;92:779-86.
102. George S, Braithwaite RA, Hughes EA. Digoxin measurements following plasma ultrafiltration in two patients with digoxin toxicity treated with specific Fab fragments. Ann Clin Biochem 1994;31:380-2.
103. Jortani SA, Miller JM, Valdes R Jr. Resolving discrepant digoxin results: a case study involving multiple interferences. J Clin Ligand Assay 1996;19:131-7.
104. Lemon M, Andrews DJ, Binks AM, Georgiou GA. Concentrations of free serum digoxin after treatment with antibody fragments. Br Med J 1987;295:1520-1.
105. Honda SA, Rios CN, Murakami L, Morita T, Scottolini AG, Bhagawan NV. Problems in determining levels of free digoxin in patients treated with digoxin immune Fab. J Clin Lab Anal 1995;9:407-12.
106. Dods HM, Norris RL, Johnson AG, Pond SM. Evaluation and comparison of the TDx II, Stratus, and Opus digoxin assays. Ther Drug Monit 1995;17:68-74.
107. Henry DW, Lacerte JA, Klutman NE, Riley CM. Irreversibility of procainamide-dextrose complex in plasma in vitro. Am J Hosp Pharm 1991;48:2426-9.
108. Valdes R Jr, Miller JJ. Importance of using molar concentrations to express cross-reactivity in immunoassays (Letter). Clin Chem 1995;41:332-3.
109. Valdes R Jr, Miller JJ. Increasing the specificity of immunoassays. J Clin Immunoassay 1992;15:87-96.
110. 1-acid glycoprotein in females and male-to-female transsexuals. Glycobiology 1996;6:407-12.
111. Echizen H, Saima S, Ishizaki T. Disopyramide protein binding in plasma from patients with nephrotic syndrome during the exacerbation and remission phases. Br J Clin Pharmacol 1987;24: 199-206.
112. Beach CL, Ludden TM, Clementi WA, Allerheligen SR. Measurement of lidocaine free concentration. Ther Drug Monit 1986;8: 326-30.
113. 1-acid glycoprotein and lidocaine in myocardial infarction. Am Coll Physicians 1980;93:701-4.
114. Edward DJ, Axelson JE, Slaughter RL, Elvin AT, Laika D. Factors affecting quínidine protein binding. J Pharm Sci 1984;73:1264-7.
115. Dasgupta A, Blackwell W, Brad D. Stability of therapeutic drug measurement in specimens collected in Vacutainer piastic blood-collection tubes. Ther Drug Monit 1996;18:306-9.
116. Robinson K, Johnston A, Walker S, Mulrow JP, McKenna WJ, Holt DW. The digoxin-amiodarone interaction. Cardiovasc Drug Ther 1989;3:25-8.
117. Partanen J, Jalava KM, Neuvonen PJ. Itraconizole increases serum digoxin concentration. Pharmacol Toxicol 1996;79:274-6.
118. Stockley IH, ed. Drug interactions: a source book of adverse interactions, their mechanisms, clinical importance and management, 2nd ed. Boston, MA: Mosby Year Book, 1991:73-99.